CLEC-1

CLEC-1 (also known as C-type lectin domain family 1 member A or CLEC1A) is a type II transmembrane protein and a member of the Dectin-1 cluster within the C-type lectin receptor (CLR) superfamily. It functions as a novel myeloid immune checkpoint and acts as an inhibitory "Don't Eat Me" signal on myeloid cells such as dendritic cells and macrophages. By binding to its ligand (CLEC-1L), which is upregulated on stressed or dying tumor cells, CLEC-1 inhibits phagocytosis by macrophages and antigen presentation by dendritic cells, thereby dampening T-cell activation and adaptive memory immune responses. Antagonist monoclonal antibodies targeting CLEC-1 have been developed to block this inhibitory pathway, restoring phagocytic function in myeloid cells and enhancing anti-tumor immunity in preclinical models. The main developer of these antagonist antibodies is OSE Immunotherapeutics[2][6][8]. Preclinical studies show that blockade of CLEC-1 synergizes with chemotherapy and tumor-targeting antibodies to increase tumor rejection[5][8].

Other names

C-type lectin domain family 1 member A